Investor Relations


Press Release

Scleroderma Two Year Data to be Presented at the 4th Systemic Sclerosis World Congress

Feb 10, 2016

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced its plans to participate in the 4th Systemic Sclerosis World Congress in Lisbon, Portugal, from February 18-20, 2016.

On Saturday, February 20, a session chaired by Dr. James Seibold and Professor Kazuhiko Takehara will focus on Emerging Therapies. Professor Guy Magalon from the Assistance Publique des Hôpitaux de Marseille (APHM) is scheduled to discuss two year data from the complete set of 12 patients treated in the SCLERADEC-I clinical study as part of a presentation entitled, “Treating Scleroderma of the Face and Hands with Fat and Stromal Vascular Fraction.” SCLERADEC-I (Principal Investigator: Professor Granel) is a French single center study aimed at measuring for the first time the safety, tolerability and potential efficacy of Cytori’s ECCS-50 locally injected in patients with hand disability due to scleroderma. ECCS – 50 was prepared in the Cell Therapy Department of APHM by the team of Professor Florence Sabatier in compliance with European regulations.

Results for the twelve patient SCLERADEC-I pilot trial were published in the August 2015 edition of Rheumatology. The data indicated that a single administration of ECCS-50 was safe and that treated patients exhibited significant improvements in hand symptoms, function and Raynaud’s Phenomena through one-year post-treatment.

Cytori will highlight the STAR and SCLERADEC-II clinical trials currently enrolling patients in the U.S. and France, respectively, at booth #3 at the Systemic Sclerosis World Congress. Cytori representatives will also be available at the booth to answer questions about the recently announced ECCS-50 Managed Access Program.

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information visit

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. These risks and uncertainties are described under the heading "Risk Factors" in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Source: Cytori Therapeutics, Inc.

Cytori Therapeutics, Inc.

Tiago Girao, 1 (858) 458-0900